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Background: Colorectal cancer (CRC) is a leading cause of cancer death globally and new biomarkers and
treatments are severely needed.
Methods: Here, we employed HCT116 and LoVo human CRC cells made resistant to either SN38 or oxaliplatin,
to investigate whether altered expression of the high affinity glutamate transporters Solute Carrier (SLC)-1A1 and
-1A3 (EAAT3, EAAT1) is associated with the resistant phenotypes. Analyses included real-time quantitative PCR,
immunoblotting and immunofluorescence analyses, radioactive tracer flux measurements, and biochemical analyses
of cell viability and glutathione content. Results were evaluated using one- and two-way ANOVA and Students
two-tailed t-test, as relevant.
Results: In SN38-resistant HCT116 and LoVo cells, SLC1A1 expression was down-regulated ~60 % and up-regulated ~4-fold,
respectively, at both mRNA and protein level, whereas SLC1A3 protein was undetectable. The changes in SLC1A1
expression were accompanied by parallel changes in DL-Threo-β-Benzyloxyaspartic acid (TBOA)-sensitive,
UCPH101-insensitive [3H]-D-Aspartate uptake, consistent with increased activity of SLC1A1 (or other family members),
yet not of SLC1A3. DL-TBOA co-treatment concentration-dependently augmented loss of cell viability induced by
SN38, while strongly counteracting that induced by oxaliplatin, in both HCT116 and LoVo cells. This reflected
neither altered expression of the oxaliplatin transporter Cu2+-transporter-1 (CTR1), nor changes in cellular reduced
glutathione (GSH), although HCT116 cell resistance per se correlated with increased cellular GSH. DL-TBOA did not
significantly alter cellular levels of p21, cleaved PARP-1, or phospho-Retinoblastoma protein, yet altered SLC1A1
subcellular localization, and reduced chemotherapy-induced p53 induction.
Conclusions: SLC1A1 expression and glutamate transporter activity are altered in SN38-resistant CRC cells. Importantly,
the non-selective glutamate transporter inhibitor DL-TBOA reduces chemotherapy-induced p53 induction and
augments CRC cell death induced by SN38, while attenuating that induced by oxaliplatin. These findings may
point to novel treatment options in treatment-resistant CRC.
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Colorectal cancer (CRC) is the fourth most common
cause of cancer death worldwide [1, 2]. Currently, treat-
ment of CRC is based on combination of 5-fluorouracil
(5-FU) and leucovorin [3–5] with other chemotherapeutic
drugs. In addition, despite frequent resistance develop-
ment, targeted treatment with the epidermal growth factor
receptor (EGFR) inhibitor cetuximab or the angiogenesis-
inhibitory antibody bevacizumab is successful in some
patients [4]. The combination treatments FOLFOX
(5-FU + leucovorin + oxaliplatin) [6] and FOLFIRI (5-
FU + leucovorin + irinotecan) [7] significantly prolong
progression-free survival in advanced CRC, the choice
between irinotecan and oxaliplatin being largely dictated by
toxicity issues [8]. Oxaliplatin is a diaminocyclohexane plat-
inum derivative which induces formation of DNA adducts,
and irinotecan is the precursor of the topoisomerase-I in-
hibitor 7-ethyl-10-hydroxycamptothecin (SN38). Both com-
pounds induce DNA damage, upregulation of p53 and
p21WAF1/Cip1, cell cycle arrest, and cell death [9–11]. The
majority of patients with metastatic CRC, whether on FOL-
FOX or FOLFIRI, will experience treatment resistance and
disease progression upon treatment, leaving only limited
additional treatment options. Possible remedies to this
include the development of drugs that do not exhibit
cross-resistance with those currently used, and of pre-
dictive biomarkers ensuring that patients receive the
treatment with the highest likelihood of effect [5]. Al-
though progress has been made in recent years, strong
biomarkers predicting response to oxaliplatin or irinote-
can are lacking and urgently needed [3, 4, 12].
To gain insight into the molecular mechanisms under-
lying chemotherapy resistance, we developed drug-resistant
human CRC cell lines based on the well-characterized
HCT116 and LoVo cell lines. Sublines resistant to SN38
and oxaliplatin, respectively, were established by long-term
exposure to increasing doses of these drugs. The cell lines
developed exhibit little cross-resistance between SN38 and
oxaliplatin [13]. Microarray analyses demonstrated marked
changes in mRNA profiles of resistant cells compared to
their parental counterparts. Among these, we noted major
changes in mRNA levels of the high affinity excitatory
amino acid transporters (or glutamate transporters) Solute
Carrier (SLC) 1A1 and -1A3 (EAAT3 and EAAT1, respect-
ively), in the resistant cell lines [13]. Studies of plasma
membrane transport proteins in chemotherapy-resistant
tumor cells have generally focused on ABC-transporters
[14, 15]. However, a number of properties make the SLC1A
family (SLC1A1-A7) very interesting in this context. Al-
though some isoforms, including SLC1A1 and SLC1A3, are
also found in peripheral tissues, the SLC1A family is by far
most widely expressed in the brain [16–18]. SLC1A family
transporters mediate cellular uptake of glutamate, driven by
3Na+,1H+ cotransport, 1 K+ counter-transport. In addition,SLC1A1 has high capacity for transporting L-cysteine, a
precursor in glutathione synthesis [16]. Slc1a1 and Slc1a3
knockout mice show retinal ganglion cell degeneration, al-
tered brain glutamate homeostasis, and increased oxidative
stress sensitivity [19], and Slc1a1 knockout mice exhibit
brain atrophy and reduced neuronal levels of the antioxi-
dant tripeptide (glutamate, cysteine, glycine) glutathione
[20], consistent with a role for these transporters in gluta-
thione synthesis. A few studies reported altered expression
and localization of glutamate transporters in CNS [21] and
non-CNS [18] cancers. Gliomas down-regulate SLC1A
family transporters and switch from net uptake to net efflux
of glutamate. This stimulates their growth and motility in
an autocrine fashion, while exerting toxic effects on sur-
rounding neurons [21–23]. Furthermore, increased levels of
reduced glutathione (GSH) have been associated with
chemotherapy resistance in several cancer types [24]. How-
ever, the possible role of glutamate transporters in CRC
chemotherapy resistance has, to our knowledge, never been
addressed.
The aim of this study was to investigate the regulation
and possible roles of glutamate transporters SLC1A1
and SLC1A3 in SN38- and oxaliplatin-resistance in
CRC. We show that SLC1A1 expression and glutamate
transporter activity are altered in a parallel manner in
SN38-resistant CRC cells. The glutamate transporter in-
hibitor DL-TBOA reduces chemotherapy-induced p53
induction and augments CRC cell death induced by
SN38, while strongly attenuating that induced by oxali-
platin. Collectively, our findings indicate that changes in
glutamate transporter expression and activity may be
relevant to the prediction and treatment of CRC chemo-
therapy resistance, and that cotreatment with DL-TBOA
may be beneficial in combination with irinotecan, but
detrimental in combination with oxaliplatin treatment.
Part of this work has previously been reported in ab-
stract form [25].
Results
Expression and activity of glutamate transporters are
altered in resistant CRC cells
Our recent microarray analysis pointed to robust changes
in the expression of glutamate transporters SLC1A1 and
SLC1A3 upon resistance development in both HCT116
cells and LoVo cells (Additional file 1: Figure S1A) [13].
Strikingly, analysis of publically available CRC patient tis-
sue data (www.oncomine.org; [26]) showed a significant
down-regulation of SLC1A1 mRNA levels in CRC com-
pared to normal tissue in 11 out of 15 datasets, while
SLC1A3 expression was generally unaltered (Additional
file 1: Figure S1B).
We therefore asked whether changes in SLC1A1 and
SLC1A3 expression were involved in resistance develop-
ment in HCT116 and LoVo cells. Consistent with the
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mRNA level was down-regulated in HCT116-SN38 cells
compared to that in parental cells (Fig. 1a). The SLC1A3
mRNA level was increased in oxaliplatin-resistant
HCT116 cells and unaffected in SN38-resistant HCT116
cells. In LoVo cells, both SLC1A1 and SLC1A3 mRNA
levels were increased in SN38-resistant cells and un-
affected in oxaliplatin-resistant cells, compared to the
levels in parental cells (Fig. 1a).
Protein levels of SLC1A1 followed the same pattern as
the mRNA levels, i.e. SLC1A1 protein expression was
down-regulated in SN38-resistant HCT116 cells, and in-
creased in oxaliplatin-resistant HCT116 cells and SN38-
resistant LoVo cells, compared to parental levels (Fig. 1b).
For SLC1A3, no protein band of the expected size was de-
tectable for either of the reported splice variants (~60 and
~55 kDa) [27], using 3 different antibodies which all gave
clear bands of correct size in positive control mouse brain
tissue (not shown). Although other scenarios are possible,
this suggests that the SLC1A3 protein level is very low in
CRC cells.
As glutamate transporter activity and membrane
localization are heavily posttranslationally regulated [28],
expression levels alone do not reveal whether transport
activity is altered. We therefore next determined glutam-
ate transporter activity (as uptake of the substrate [3H]-D-
Asp following a 6-min incubation in buffer supplemented
with a tracer concentration of 100 nM [3H]-D-Asp). Data
are shown in Fig. 1c, d and Table 1. In parental HCT116
and LoVo cells, [3H]-D-Asp uptake was competitively
inhibited by the substrate L-glutamate, with IC50 values of
20–30 μM. To determine which transporter(s) was re-
sponsible for the [3H]-D-Asp uptake, we assessed the ef-
fect of DL-TBOA, a nonselective inhibitor of EAATs, and
UCPH-101, a specific SLC1A3 inhibitor [16, 28, 29]. IC50
values of DL-TBOA for SLC1A1 and SLC1A3 in uptake
assays are in the low micromolar range, depending on the
system and experimental setup [30, 31], whereas UCPH-
101 exhibits high-nanomolar IC50 values for SLC1A3 and
is inactive at SLC1A1 at concentration up to > 400 fold
higher [29]. In all cell lines, basal [3H]-D-Asp uptake was
inhibited by DL-TBOA with IC50 values around 2 μM,
whereas it was essentially unaffected by UCPH-101 at
concentrations up to 100 μM. Basal [3H]-D-Asp uptake
was decreased by about 60 % in SN38-resistant compared
to parental HCT116 cells, whereas that in SN38-resistant
LoVo cells was nearly tripled compared to parental LoVo
cells. In the oxaliplatin-resistant cell lines, [3H]-D-Asp up-
take was slightly decreased in the HCT116 model, and un-
altered in the LoVo model.
Collectively, these data show that SLC1A1 mRNA and
protein expression and DL-TBOA-sensitive, UCPH-101-
insensitive [3H]-D-Asp uptake are decreased in SN38-
resistant HCT116 cells and increased in SN38-resistantLoVo cells, compared to their parental controls, while
neither SLC1A3 protein or activity could be detected in
any of the cell lines.
Viability of SN38- and oxaliplatin-resistant CRC cells is dif-
ferentially affected by DL-TBOA
To determine whether glutamate transporter activity
contributed to the SN38- and oxaliplatin-resistant phe-
notypes, we next assessed viability, first by MTT assay
(Fig. 2). Viability of parental HCT116 (Fig. 2a, b) and
LoVo (Fig. 2e, f ) cell lines was reduced after 48 h expo-
sure to SN38 or oxaliplatin, with about 20 % viable cells
remaining after 48 h at the highest dose tested (0.8 μM
SN38 or 20 μM oxaliplatin, respectively). Addition of
DL-TBOA (70 or 350 μM) concomitantly with the che-
motherapeutic drugs if anything slightly exacerbated the
SN38-induced loss of viability in parental cell lines
(Fig. 2a, e). In contrast, DL-TBOA counteracted the ef-
fect of oxaliplatin on viability in both parental cell lines
(Fig. 2b, f ). This was particularly evident in LoVo cells,
in which 350 μM DL-TBOA essentially abolished the
loss of viability induced by 0.8 μM oxaliplatin (Fig. 2f ).
Notably, the DL-TBOA-induced increase in viability was
specific to oxaliplatin-treated cells, as untreated cells
consistently showed a small decrease in viability upon
DL-TBOA treatment (Fig. 2a-h).
We next determined whether SN38- and oxaliplatin-
resistance was associated with changes in the impact of
DL-TBOA on viability. Indeed, in SN38-resistant HCT116
(Fig. 2c) and LoVo (Fig. 2g) cells, concomitant DL-TBOA
treatment concentration-dependently enhanced SN38-
induced loss of viability. Conversely, in oxaliplatin-
resistant HCT116 (Fig. 2d) and LoVo (Fig. 2h) cells,
DL-TBOA reversed oxaliplatin-induced loss of viability.
The MTT assay measures mitochondrial conversion of
tetrazolium salt to formazan [32]. Although this is gener-
ally a good measure of cell viability, artifacts can arise if
mitochondrial activity changes without parallel changes in
viability. To determine viability by an independent method
we therefore DAPI-labeled nuclei and quantified the sur-
viving, still adherent cells by high-throughput confocal mi-
croscopy. The opposite effects of DL-TBOA on SN38-
and oxaliplatin-induced loss of viability are also evident in
this assay, strongly indicating that the effects of DL-TBOA
primarily reflect changes in cell viability (Additional file 2:
Figure S2).
Taken together, this data shows that DL-TBOA en-
hances SN38-induced, and counteracts oxaliplatin-induced,
cell death.
Expression of the Cu2+ transporter CTR1 is unaffected by
DL-TBOA
The marked and specific reversal of oxaliplatin-induced
cell death by DL-TBOA suggested that an oxaliplatin
Fig. 1 (See legend on next page.)
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Fig. 1 Expression and activity of SLC1A1 and SLC1A3 is altered in SN38- and oxaliplatin-resistant CRC lines. a Relative mRNA levels of SLC1A1
and SLC1A3 in parental (PAR), SN38- and oxaliplatin-resistant HCT116 and LoVo cells, determined by qPCR analysis. b Protein levels of SLC1A1
in parental, SN38- and oxaliplatin-resistant HCT116 and LoVo cells relative to that in their parental counterparts. Representative Western blots
(p150 serves as a loading control) and densitometric quantification of the Western blot data are shown. The qPCR and Western blot data
represent 3 independent experiments per condition. *) p < 0.05, **) p < 0.01, and ***) p < 0.001, compared to parental cells by one-way ANOVA
and Dunnett post-test. c-d [3H]-D-Asp uptake level in parental (PAR), SN38- and oxaliplatin-resistant HCT116 and LoVo cells in the [3H]-D-Asp
uptake assay. Concentration-inhibition curves for L-Glutamate (L-Glu), DL-TBOA (TBOA) and UCPH-101 in parental, SN38- and oxaliplatin-resistant
HCT116 and LoVo cells, respectively. Values are based on four experiments each performed in duplicate
Pedraz-Cuesta et al. BMC Cancer  (2015) 15:411 Page 5 of 17import mechanism might be inhibited by DL-TBOA.
The high-affinity Cu2+ transporter CTR1 is a major such
pathway [33]. We therefore hypothesized that DL-
TBOA-induced rescue of CRC cells from oxaliplatin-
induced death might reflect CTR1 down-regulation. To
avoid confounding effects of the substantial death induc-
tion seen at 48 h, CTR1 levels were assessed after 24 h
of chemotherapy +/− DL-TBOA. Oxaliplatin treatment
tended to reduce CTR1 protein expression in all cell
lines except parental HCT116, HCT116-Oxa, and LoVo-
Oxa cells, yet without detectable effects of DL-TBOA on
the CTR1 protein level (Fig. 3).
Cellular GSH is increased in resistant HCT116 cells, but
only marginally affected by DL-TBOA
In light of the importance of SLC1A1 in regulation of
L-cysteine transport and cellular GSH homeostasis [16,
19, 20] and the role of increased GSH levels in chemo-
therapy resistance in several cancer types [24], we next
asked whether resistance development and DL-TBOA
treatment were associated with changes in cellular GSH
level. Notably, the steady state intracellular GSH level
was increased in both SN38- and oxaliplatin-resistant
HCT116 cells, yet unaltered in the resistant LoVo strains
(Fig. 4a). After a 24 h treatment with SN38 or oxalipla-
tin, parental HCT116 cells showed slightly increased
GSH levels, and a trend towards decreased GSH levels
was seen in SN38 resistant cells (Fig. 4b). In contrast,
oxaliplatin-resistant HCT116 cells (Fig. 4b) and all LoVo
cell lines (Fig. 4c) showed no detectable changes inTable 1 Summary of pharmacological properties and basal level [3H
Substrate/Inhibitor
cell line L-Glu (μM) IC50[pIC50 ± S.E.M.] UCPH (μM) IC50[pIC50 ±
HCT116-PAR 21 [4.67 ± 0.04] >100 [<4.0]
HCT116-SN38 21 [4.67 ± 0.01] >100 [<4.0]
HCT116-Oxa 21 [4.67 ± 0.01] >100 [<4.0]
LoVo-PAR 26 [4.59 ± 0.04] >100 [<4.0]
LoVo-SN38 28 [4.54 ± 0.10] >100 [<4.0]
LoVo-Oxa 23 [4.64 ± 0.06] >100 [<4.0]
IC50 values for the three compounds are in μM, with pIC50 values in brakets. The ba
chemotherapeutic-cells normalized to that in the relevant parental cell line on the e
Compared to parental cell by two-tailed Student’s t-testcellular GSH levels upon treatment. There was no de-
tectable effect of DL-TBOA on GSH levels.
p53 induction by SN38 and oxaliplatin is decreased by
DL-TBOA
We next explored the impact of SN38, oxaliplatin and
DL-TBOA on protein levels of p53 and p21WAF1/Cip
(p21), major cell survival- and proliferation regulators
induced by DNA damage after SN38 and oxaliplatin
treatment [9–11], and on PARP-1 cleavage, a well-
characterized indicator of apoptosis induction. In paren-
tal HCT116 cells, p53 and p21 were markedly induced
by 24 h treatment with SN38 or oxaliplatin (Fig. 5a and
Additional file 3: Figure S3), consistent with the known
DNA damage induction by both drugs [9–11]. In SN38-
resistant HCT116 cells, this response to oxaliplatin was
retained, while, as expected, SN38 had essentially no
effect on p53 expression, yet modestly increased p21
expression. Conversely, in oxaliplatin-resistant cells,
only SN38 induced p53 and p21 expression (Fig. 5a and
Additional file 3: Figure S3). PARP-1 cleavage was in-
duced by SN38 in parental and oxaliplatin-resistant, yet
not in SN38-resistant, cells (Additional file 3: Figure S3).
A comparable pattern was seen for the LoVo cell lines
(Fig. 5b and Additional file 4: Figure S4). Notably, treat-
ment with DL-TBOA concomitant to the chemothera-
peutic compounds induced an apparent decrease in p53
induction compared to chemotherapy alone, in both par-
ental and drug-resistant cell lines (Fig. 5a, b). As p53 af-
fects both proliferation and death pathways, we next]-D-Asp uptake
S.E.M.] TBOA (μM) IC50[pIC50 ± S.E.M.] Basal Uptake [% of parental]
1.8 [5.75 ± 0.03] 100
1.5 [5.83 ± 0.08] 40 ± 1.8***
1.5 [5.75 ± 0.08] 73 ± 6.9*
1.4 [5.84 ± 0.03] 100
1.9 [5.83 ± 0.11] 275 ± 35**
2.7 [5.75 ± 0.03] 97 ± 8.0 NS
sal [3H]-D-Asp uptake data are based on the measured uptake in the
xperiment performed in duplicate. *) p <0.05,**) p <0.01,and ***) p <0.001,
Fig. 2 (See legend on next page.)
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Fig. 2 DL-TBOA augments SN38-induced death in SN38-resistant cells, but protects oxaliplatin-resistant cells from oxaliplatin-induced death. Parental
and drug-resistant HCT116 and LoVo cell lines seeded in 96-well dishes were exposed to SN38 (0.1 or 0.8 μM) or oxaliplatin (0.8 or 20 μM), alone or in
combination with 70 or 350 μM DL-TBOA as indicated, for 48 h. Viability was assessed by MTT assay. a-b Parental HCT116 cells, (c) SN38 resistant
HCT116 cells, (d) Oxaliplatin-resistant HCT116 cells, (e-f) Parental LoVo cells, (g) SN38 resistant LoVo cells, (h) Oxaliplatin-resistant LoVo cells. Data
are means with S.E.M. error bars of 3 independent experiments. *) p < 0.05, **) p < 0.01, ***) p < 0.001 compared to the control group without
drug or TBOA treatment; #) p < 0.05 compared to controls without TBOA treatment. One-way ANOVA followed by Dunnett post-test
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retinoblastoma protein phosphorylation on Ser 807/811
(pRb) as a well-established marker of active cell cycling
(Additional file 5: Figure S5). In the resistant (but, unex-
pectedly not in the parental), cell lines, the pRb levelFig. 3 Effect of acute DL-TBOA and chemotherapy treatment on CTR1 prot
were exposed to SN38 (0.8 μM) or oxaliplatin (20 μM), alone or in combina
protein per lane were separated by SDS-PAGE and the protein levels of CT
blots (tubulin serves as a loading control), bottom: Densitometric quantifica
Quantitative data are means with S.E.M. error bars of 3 independent experi
group without drug or TBOA treatment. Two-way ANOVA with Tukey post-was decreased by the chemotherapy treatment to which
the cell lines were sensitive, confirming that the treat-
ments impact on proliferation. While these effects did
not reach statistical significance, DL-TBOA also tended
to increase pRb levels under control conditions in bothein level. Parental and drug-resistant HCT116 (a) and LoVo (b) cell lines
tion with 350 μM DL-TBOA as indicated for 24 h. Equal amounts of
R1 were determined by Western blotting. Top: Representative Western
tion data summarized from 3 independent experiments per condition.
ments. *) p < 0.05, **) p < 0.01, ***) p < 0.001 compared to the control
test
Fig. 4 Effect of glutamate transporter inhibition on cellular GSH
levels. a Basal intracellular GSH levels were measured as described in
Materials and Methods, and normalized to total protein in the
samples. b-c Normalized basal GSH levels under control conditions,
in HCT116 and LoVo parental and resistant cells after 24 h of
treatment with 0.8 μM SN38 or 20 μM oxaliplatin, in absence or
presence of DL-TBOA (350 μM) as shown. * p < 0.05 vs untreated
control group (n = 5). One-way ANOVA followed by
Dunnett post-test
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pRb levels after oxaliplatin treatment in all cell types ex-
cept oxaliplatin-resistant HCT116 cells.
Effects of SLC1A1 knockdown and -overexpression on
SN38- and oxaliplatin-induced cell death
DL-TBOA is a non-selective inhibitor of all SLC1A iso-
forms, thus the observed effects of DL-TBOA in the cells
could potentially arise from its activity at SLC1A1, −A2,
and/or -A6–7, whereas the lack of effect of UCPH-101
rules out the involvement of SLC1A3. We therefore asked
whether p53 levels were similarly affected by siRNA-
mediated SLC1A1 knockdown. About 50 % and 30 %
SLC1A1 knockdown was obtained in resistant HCT116
and LoVo cell lines, respectively (Fig. 6). In LoVo, but not
in HCT116 cells, SLC1A1 knockdown tended to reduce
the oxaliplatin-induced increase in p53 protein level seen
after DL-TBOA treatment, however, this effect was less
marked than that seen after DL-TBOA treatment (com-
pare with Fig. 5). Overexpression of SLC1A1 had no de-
tectable effect on p53, p21, or PARP cleavage in any of the
cell lines (Additional file 6: Figure S6).
Effects of SN38-, oxaliplatin and DL-TBOA on subcellular
localization of SLC1A1 in HCT116 cells
To address the question of whether altered SLC1A1
localization was involved in the effects of SN38, oxaliplatin
and DL-TBOA, we performed immunofluorescence ana-
lysis of the parental and resistant cell lines, in absence and
presence of chemotherapeutics and DL-TBOA. SLC1A1
localization is shown in Fig. 7. In Additional file 7: Figure
S7 the same images are shown merged with DAPI and
F-actin staining. SLC1A1 is predominantly localized in
intracellular vesicles, from where it undergoes regulated
trafficking to the plasma membrane upon specific stimuli
[34]. In agreement with this, SLC1A1 localized partially to
the membrane and partially in a cytosolic compartment
in both parental and SN38-resistant cells under control
conditions (Fig. 7a). In contrast, in oxaliplatin-resistant
cells, SLC1A1 staining was predominantly seen in the peri-
nuclear/nuclear region under control conditions (Fig. 7a).
In parental cells, treatment with SN38 or oxaliplatin in-
duced a marked shift in SLC1A1 localization towards
the perinuclear/nuclear region (Fig. 7b, c). In these cells,
DL-TBOA had no detectable effect on SLC1A1 localization,
either alone or in combination with the chemotherapeutic
agents (Fig. 7a-c). In SN38-resistant cells, addition of DL-
TBOA to the chemotherapeutic treatment increased the
fraction of SLC1A1 fluorescence localized to the peri-
nuclear/nuclear compartment, and a similar trend was seen
with DL-TBOA alone (Fig. 7a, b). Notably, in oxaliplatin-
resistant cells, a greater fraction of SLC1A1 was intracellu-
lar under control- and oxaliplatin-treated conditions, and
this was partially reversed by DL-TBOA (Fig. 7a, c).
Fig. 5 Effects of DL-TBOA on cell death and survival parameters after chemotherapy treatment. Parental and drug-resistant HCT116 (a) and LoVo
(b) cell lines were exposed to SN38 (0.8 μM) or oxaliplatin (20 μM), alone or in combination with 350 μM DL-TBOA as indicated, for 24 h. Equal
amounts of protein per lane were separated by SDS-PAGE and the protein level of p53 was determined by Western blotting. Top: Representative
Western blots, with p150 as loading control. Bottom: Densitometric quantifications based on 3 independent experiments per condition. Data are
means with S.E.M. error bars of 3 independent experiments. *) p < 0.05, **) p < 0.01, ***) p < 0.001,****) p < 0.0001 compared to the control group
without drug or TBOA treatment; Two-way ANOVA with Tukey post-test
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Resistance to irinotecan (of which SN38 is the active
metabolite) and oxaliplatin is a major problem in CRC
treatment, and the mechanisms of resistance remain in-
completely understood. A major finding of this study is
the striking difference between the effects of the glutamatetransport inhibitor DL-TBOA on viability after SN38- and
oxaliplatin treatment: DL-TBOA modestly exacerbated
the loss of viability in untreated or SN38-treated cells,
whereas it markedly counteracted oxaliplatin-induced cell
loss. This suggests that glutamate transporter activity has
a specific, negative impact on oxaliplatin-induced death,
Fig. 6 Effects of SLC1A1 siRNA on cell death and survival parameters after chemotherapy treatment. Drug-resistant HCT116 and LoVo cell lines
were transfected with siRNA against SLC1A1 or corresponding mock siRNA (siCtrl.). 24 h later, cells were exposed to SN38 (0.8 μM), oxaliplatin
(20 μM) as indicated, for 24 h. Equal amounts of protein per lane were separated by SDS-PAGE and the protein level of SLC1A1 and p53 was
determined by Western blotting. a Representative Western blots, with p150 as loading control. b Densitometric quantifications of relative p53
protein level, based on 3 independent experiments per condition. Data are means with S.E.M. error bars of 3 independent experiments. *)
p< 0.05, **) p< 0.01, ***) p< 0.001,****) p< 0.0001 compared to the control group without drug or TBOA treatment; Two-way ANOVA with Tukey post-test
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treated and SN38-treated cells (which may also be present
in oxaliplatin-treated cells but be masked by the strong,
opposite effect).
SLC1A1 expression and glutamate transporter activity are
altered in SN38-resistant CRC cells
The SLC1A1 protein levels paralleled its mRNA levels,
whereas SLC1A3 protein expression was not detectable.
Basal glutamate transporter activity largely, but not com-
pletely, paralleled SLC1A1 expression and was inhibitedby L-glutamate and by the broad glutamate transporter
inhibitor DL-TBOA, but not by UCPH-101, a specific
SLC1A3 inhibitor. Collectively, this suggests that SLC1A1
is at least partially responsible for the observed glutamate
transporter activity. Although this is, to our knowledge,
the first study to demonstrate SLC1A1 protein and activity
changes in drug-resistant cancer cells, altered SLC1A1
mRNA expression was also reported in ovarian cancer
cells and in the NCI-60 cancer cell line panel [14, 15], sug-
gesting a more widespread relevance than CRC. In both
HCT116 and LoVo cells, changes in [3H]-D-Asp uptake
Fig. 7 Subcellular localization of SLC1A1 in parental and resistant CRC cells – effects of chemotherapy and DL-TBOA. a Immunofluorescence
images of parental (PAR), SN38 resistant and oxaliplatin resistant HCT116 cells treated or not for 48 h with 350 μM DL-TBOA, and stained with
antibody against SLC1A1. b Parental and SN38-resistant HCT116 cells treated for 48 h with 0.8 μM SN38 in the absence or presence of 350 μM DL-TBOA,
and stained as in A. c Parental and oxaliplatin-resistant HCT116 cells treated for 48 h with 20 μM oxaliplatin in the absence or presence of 350 μM DL-TBOA,
and stained as in A. All conditions are representative of 2 or 3 independent biological replicates in duplicate. Scale bar: 10 μm. Additional file 7:
Figure S7 shows the same images, merged with staining for DAPI and Rhodamine-conjugated phalloidin to visualize localization of nuclei and
F-actin, respectively
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more pronounced than the changes in SLC1A1 protein
level, and in oxaliplatin-resistant HCT116 cells, SLC1A1
expression was modestly increased, yet [3H]-D-Asp uptake
modestly decreased. While not further addressed here,
this suggests an additional role for posttranslational regu-
lation of SLC1A1 activity, and/or, contributions from
other SLC1A isoforms.
Possible mechanisms involved in the effect of glutamate
transporter inhibition on viability
We first hypothesized that the rescue of oxaliplatin-
treated cells by DL-TBOA might reflect a dependence of
oxaliplatin influx pathway(s) on glutamate transporter ac-
tivity. The protein level of the major such pathway, CTR1,
was modestly decreased by oxaliplatin treatment, yet was
not regulated by DL-TBOA. Another possibility was that
SLC1A1 might modulate cellular GSH levels, which also
regulate oxaliplatin uptake via CTR1 [35]. SLC1A1 can
directly transport L-cysteine and plays a major role in sup-
porting GSH production [16, 19, 20], and also SLC1A1-
mediated changes in extracellular glutamate signaling
could contribute, under conditions where extracellular
glutamate availability is a limiting factor. Multiple compo-
nents of the glutamate signaling machinery are expressed
in the colon epithelium, including, in addition to glutam-
ate transporters [17], NMDA receptors (NMDARs) [36]
and metabotropic glutamate receptors [37]. Indeed,
NMDAR- and mGluR-antagonists inhibit the proliferation
of HT29 cells [37]. On the other hand, excessive NMDAR
activation induces increased [Ca2+]i and consequent cell
death in CRC cells [36]. Similarly, glutamate release auto-
crinely stimulates gliomas, yet is toxic to surrounding neu-
rons [21–23]. Our microarray data [13] support the
notion that glutamate- and glutathione homeostasis are
broadly altered in the SN38- and oxaliplatin resistant CRC
cells, in agreement with previous studies showing in-
creased GSH levels and γ-GCS up-regulation in drug-
resistant cancer cells [38]. Of note, the SN38-resistant
LoVo cells, which exhibited a 4-fold increase in SLC1A1
expression, also show up-regulation of both mGluR and
iGluR [13]. Also glutamate decarboxylase, which is rate-
limiting for GABA production and was recently assigned
important roles in small-cell lung cancer [39], shows in-
creased expression in several of the resistant cell lines, as
does the GSH-dependent ABCC2/MRP2 GS-X drug efflux
pump [13]. Further supporting the notion that a change
in basal GSH metabolism contributes to the resistant
phenotype, cellular GSH was increased in SN38- and
oxaliplatin-resistant HCT116, yet this did not correlate
with the effects of DL-TBOA treatment on viability.
p53 induction by chemotherapeutic treatment was re-
duced by DL-TBOA in both HCT116 and LoVo cells.
This differs from the opposite effects of DL-TBOA onviability in HCT116 and LoVo cells, thus, the specific
mechanisms involved in the latter must be cell type-
dependent and/or upstream of p53. Effects related to the
cotransport of Na+ and H+ by the glutamate transporters
may also be envisaged. Thus, in mouse astrocytes, glu-
tamate uptake reduced cytosolic and mitochondrial pH
and inhibited oxidative metabolism in a manner inhib-
ited by DL-TBOA and only in cells expressing the glu-
tamate transporters [40]. Other mechanisms previously
implicated in oxaliplatin resistance include upregulation
of Breast Cancer Resistance Protein (BCRP, ATPG2) and
increased DNA-damage repair via up-regulation of Exci-
sion Repair Cross Complementing Protein 1 (ERCC1)
[41], whereas SN38 resistance was proposed to involve
down-regulation of topoisomerase-I [41]. Future studies
should establish the possible link of these mechanisms
to altered glutamate transporter activity.
Finally, the subcellular localization of SLC1A1 was altered
in chemotherapy-resistant cells as well as by treatment
with chemotherapy or DL-TBOA. Chemotherapy treatment
(a reduction in viability), was associated with a shift of
SLC1A1 towards a perinuclear/nuclear localization, except
in HCT116-Oxa cells, in which SLC1A1 was perinuclear/
nuclear already prior to treatment. Notably, the effects of
DL-TBOA on SLC1A1 localization and cell viability corre-
lated: In SN38-resistant cells, DL-TBOA augmented both
SN38-induced loss of viability and chemotherapy-induced
nuclear/perinuclear shift of SLC1A1, and in oxaliplatin-
resistant cells, DL-TBOA counteracted both oxaliplatin-
induced loss of viability and nuclear/perinuclear SLC1A1
localization. The mechanism involved cannot be deduced
from the present studies, yet it is notable that regulated
nuclear localization of SLC1A3 (GLAST-1) in cancer
cells has been reported independently by two groups
[18, 21]. Ye et al. [21] showed that SLC1A3 localized to
the nucleus in glioma cells and glioblastoma patient
brain tissue, but to the plasma membrane in normal as-
trocytes and normal brain tissue. Varini et al. [18]
showed that nuclear localization of SLC1A3 was associ-
ated with reduced cell density/loss of cell-cell contacts.
Neither study provided direct evidence to the mecha-
nisms involved in this phenomenon, but if SLC1A1
localization is similarly regulated by cell-cell contacts,
this might suggest that the translocation is downstream
of reduced cell numbers in response to chemotherapy
treatment, and also this interpretation is consistent with
the precise correlation between the effect of DL-TBOA
on viability and on SLC1A1 localization.
Possible involvement of other excitatory amino acid
transporters in the effects of DL-TBOA
The effect of DL-TBOA was concentration-dependent in
the range congruent with known IC50-values for inhib-
ition of SLC1A1, yet only a partially similar pattern was
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sible, therefore, that the effect of DL-TBOA involved other
excitatory amino acid transporters than SLC1A1, and
nonspecific effects can obviously not be excluded. How-
ever, the fact that DL-TBOA was always protective in
oxaliplatin-treated, and always detrimental in SN38-
treated, cells suggests that glutamate transporter inhib-
ition impacts on a drug-specific, upstream mechanism,
either at the level of drug influx/efflux, or, less likely, at
the level of upstream interactions with the chromatin
and associated DNA damage. Notably, public database in-
formation indicates that SLC1A1 is frequently down-
regulated in CRC tumors (Additional file 1: Figure S1;
www.oncomine.org; [42]). It is therefore tempting to
speculate that in some CRC patients, this may confer a
growth advantage similar to that exerted by DL-TBOA
after oxaliplatin treatment. Future studies should assess
excitatory amino acid transporter levels in CRC tumors from
SN38- and oxaliplatin resistant and non-resistant patients.
Conclusions
In conclusion, SLC1A1 expression and glutamate trans-
porter activity are altered in SN38-resistant CRC cells,
and the glutamate transporter inhibitor DL-TBOA re-
duces chemotherapy-induced p53 induction and aug-
ments CRC cell death induced by SN38, while strongly
attenuating that induced by oxaliplatin. Our findings in-
dicate that changes in glutamate transporter expression
and activity may be relevant in CRC, diagnostically and
in the context of choice of treatment regimen.
Methods
Reagents
SN38 was from Sigma-Aldrich, oxaliplatin from Sanofi-
Aventis, and DL-Threo-β-Benzyloxyaspartic acid (DL-
TBOA) from Tocris. UCPH101 was synthesized as
described [29]. Primary antibodies were from Santa Cruz
Biotechnology (SLC1A1, p21WAF1/Cip1 (p21) and CTR1),
BD Transduction (p150), Cell Signaling Technology
(poly-(ADP-ribose) polymerase-1 (PARP-1), phospho-Ser807/
811-retinoblastoma protein, and p53). Rhodamine-phalloidin
was from Invitrogen, and AlexaFluor488-conjugated sec-
ondary antibody from Life Technologies. 4',6-diamidino-
2-phenylindole (DAPI) was from Invitrogen. Alkaline
phosphatase-coupled secondary antibodies were from Sigma-
Aldrich. [3H]-D-Aspartic acid ([3H]-D-Asp) was from PerkinElmer.
Cell lines and treatments
HCT116 human CRC cells originate from a primary
colon carcinoma [43], and LoVo cells from a metastatic
nodule from a CRC patient [44]. Both cell lines are
metastatic in xenograft models [45]. HCT116 cells were
obtained from the NCI/Development Therapeutics Pro-
gram, and LoVo cells from the American Tissue CultureCollection. The cell line identities of parental and resist-
ant cell lines were confirmed using short tandem repeat
DNA analysis (IdentiCell Cell Line Authentication Ser-
vice, Aarhus University Hospital, Aarhus, Denmark). In
addition, all cell lines were regularly assessed to be
mycoplasma-free. HCT116 and LoVo sub-lines resistant
to SN38 and oxaliplatin (hereafter denoted HCT116-
SN38, HCT116-Oxa, LoVo-SN38 and LoVo-Oxa), re-
spectively, were established by exposing parental
HCT116 and LoVo cell lines to increasing doses of the
respective chemotherapeutics for at least 45 passages
[13]. Cells were grown in RPMI 1640 + Glutamax™, 10 %
Foetal Bovine Serum (FBS), and 1 % Penicilin/Strepto-
myocin (Life Technologies) at 5 % CO2, 37 °C, and prop-
agated by gentle trypsination every 3–4 days. Unless
otherwise specified, experiments were carried out at 37 °C.
Real-time quantitative PCR (qPCR) analysis
Total RNA was purified using the Machery-Nagel
NucleoSpin® RNA II kit. cDNA was synthesized using
SuperScript II RT (Invitrogen) and random primers.
qPCR was carried out in triplicate in an ABI7900 Real
Time PCR machine, using FastStart universal SYBR Green
master mix (Roche Applied Bioscience), and 0.2 μM for-
ward and reverse primers. Thermal profile was: 96 °C
10 min (96 °C 1 min, 60 °C 30 s, 72 °C 1 min) × 40.
Normalization was done to GAPDH, PBGD and β-actin









ATTTC-3'. Melting curves confirmed the presence of only
one amplicon. Relative expression ratios were calculated
as in [46].
Immunoblotting
Cells were grown to a confluence of 60-80 % and treated
with chemotherapy, siRNA- or plasmid transfection as
indicated. Cells were washed once in PBS, lysed in lysis
buffer (1 % SDS, 0.1 M Tris pH 7.5, and 1 mM Na3VO4),
sonicated, and protein content determined (DC assay,
BioRad). Lysates were mixed 2:1with NuPage LDS sam-
ple buffer (Invitrogen). SDS-PAGE was carried out in
NOVEX chambers with NuPAGE 10 % Bis-Tris gels
under reducing and denaturing conditions, using Bench-
Mark protein ladder (Invitrogen), and 15 μg protein per
lane. Proteins were transferred to PVDF membranes,
which were Ponceau S stained, blocked for 1 h at 37 °C
in 5 % nonfat dry milk in TBST (0.01 M Tris/HCl,
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night at 4 °C with primary antibodies diluted in blocking
buffer, washed in TBST, incubated with secondary anti-
bodies for 1 h, washed in TBST, and developed using
BCIP/NBT (KPL). Bands were scanned and quantified
using UN-SCAN-IT (Silk Scientific).
Cell viability assays
Cells were seeded at appropriate density (LoVo 10,000,
and HCT116 5000 cells /100 μl) in growth medium in
96-well plates. Next day, cells were treated with inhibi-
tors and/or chemotherapy in a total volume of 200 μl in
growth medium and incubated for 48 h at 37 °C, 5 %
CO2. The medium was replaced with 100 μl of 0.5 mg/
ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) in growth medium. The reaction was
stopped 1.5-2.5 h later by addition of 100 μl 20 % SDS
in 0.02 M HCl, and incubation overnight to allow
complete lysis of cells and formazan crystals. Absorb-
ance was measured in an ELISA plate reader (Thermo
Scientific MultiScan FC) at 550 nm. Data were back-
ground subtracted and % viability relative to controls
calculated.
Cell counting using the OPERA high throughput confocal
Cells were seeded in 96-well plates (Greiner Bio) one
day prior to experiments. Cells were treated with
chemotherapy and/or inhibitors as indicated and incu-
bated for 48 h. Medium was aspirated, and cells were
washed gently in ice cold PBS, fixed in 2 % paraformal-
dehyde, washed in PBS, and nuclei stained by 5 min in-
cubation with DAPI. Plates were scanned using an
OPERA high-throughput microscope (PerkinElmer). Nu-
cleus counting was performed using proprietary OPERA
software, based on 100 points per well, and cell counts
from non-treated cells as controls.
Constructs, siRNA and transfection
50 nM of non-specific siRNA (Eurofins MWG Operon,
#10-5394-1/1) or SLC1A1 siRNA (GTGTTATATGCC
ACTAGGT; Mission siRNA, Sigma-Aldrich) was trans-
fected using Lipofectamine 2000, into 40-50 % confluent
LoVo and HCT116 cell lines. For overexpression, cells
were transfected with full-length SLC1A1 in pcDNA3.1
[30] using 1 μg of DNA per well of a 6-well plate, and
Lipofectamine 2000. 48 h after transfection, cells were
treated with oxaliplatin or SN38 as indicated, and 24 h
later, lysed for immunoblotting.
[3H]-D-Asp uptake assay
The [3H]-D-Asp uptake assay was performed essentially
as in [30]. Briefly, cells were split into poly-D-lysine-
coated white 96-well plates (PerkinElmer). A similar
number of cells were seeded for HCT116 parental,HCT116-SN38 and HCT116-Oxa cell lines (7 × 104
cells/well) and LoVo parental, Lovo-SN38 and Lovo-Oxa
cell lines (6 × 104 cells/well). 16–24 h later, culture
medium was aspirated, and cells were washed once with
100 μl assay buffer (Hank’s Buffered Saline Solution sup-
plemented with 20 mM HEPES, 1 mM CaCl2 and 1 mM
MgCl2, pH 7.4). 50 μl assay buffer supplemented with
100 nM [3H]-D-Asp and test compounds as indicated
was added, and the plate was incubated at 37 °C for
6 min. Non-specific [3H]-D-Asp uptake was determined
in wells with 3 mM L-glutamate. The assay mixture was
quickly removed, and wells were washed with 2 × 100 μl
ice-cold assay buffer, followed by 150 μl Microscint™20
scintillation fluid (PerkinElmer). The plate was shaken
for 1 h and counted in a Wallac 1450 MicroBeta Trilux
scintillation counter (GMI, Ramsey, MN).
Measurement of cellular glutathione levels
Cells were seeded in 24-well plates (104 cells per well),
treated the next day with chemotherapy and/or DL-
TBOA and incubated for 24 h. Medium was removed
and cells were washed twice with ice-cold PBS, which
was removed and 500 μl ice-cold 1 % Sulfosalicylic acid
was added per well. Cells were incubated on ice for at
least 10 min. After centrifugation (1 min, 15,000 g),
10 μl lysate was used to determine total GSx content. To
measure GSSG content, 130 μl sample was mixed with
55 μl 0.2 M Tris (pH 9) and 5 μl 2-Vinylpyridine. Tubes
were vortexed carefully and incubated for at least 1 h at
room temperature. 10 μl of this mix was mixed first with
90 μl of water in a 96-well plate and then with a reaction
mix (0.1 M sodium phosphate buffer pH 7.5 containing
1 mM EDTA, 10 mM NADPH, 10 mM DTNB and
0.05 μl Glutathione reductase, 2U/μl). Measurements
were taken every 30 s for 10 min in an ELISA plate
reader (Thermo Scientific MultiScan FC) at 405 nm ab-
sorbance. GSH values were obtained by subtraction of
GSSG values from GSx values.
Immunofluorescence analysis of SLC1A1
Immunofluorescence analysis was carried out essentially
as in [47]. Cells grown on glass coverslips were fixed in
2 % paraformaldehyde, washed in TBST, permeabilized
for 5 min (0.5 % Triton X-100 in TBST), blocked for
30 min in 5 % BSA in TBST, incubated with SLC1A1
primary antibody in TBST + 1 % BSA overnight at 4 °C,
washed in TBST, and with Rhodamine-phalloidin and
AlexaFluor488 conjugated secondary antibody (1:600 in
TBS + 1 % BSA) for 1 h, followed by washing in TBST,
and mounting in N-propyl-galleate mounting medium
(2 % w/v in PBS/glycerol). DAPI was added for 3 min
following incubation with the secondary antibody. Cells
were visualized using the 60X/1.35 NA objective of an
Olympus Bx63 epifluorescence microscope. No/negligible
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Overlays were carried out using Adobe Photoshop soft-
ware. No other image adjustment was performed.
Statistical analysis
Statistical analysis was carried out in Graphpad Prism-6,
using one-way ANOVA with Dunnett post-test, two-way
ANOVA with Tukey post-test, or Students two-tailed
t-test, as indicated.
Ethics statement
No human material or human data except established
cell lines and publically available information from the
Oncomine database were used in the present study.
Additional files
Below is the link to the electronic supplementary material.
Additional file 1: Figure S1. Microarray and Oncomine data showing
the expression pattern of SLC1A1 and SLC1A3. (A) Microarray data
showing the fold change in expression of SLC1A1 and SLC1A3 in
SN38- and oxaliplatin (Oxa)-resistant HCT116 and LoVo cell lines compared
to respective parental cell line. Data are from [13]. (B) The figure summarizes
data from 15 different studies, showing the mRNA expression of SLC1A1
and SLC1A3 in CRC tissue relative to that in normal tissue. As seen,
SLC1A1 was nearly ubiquitously downregulated, while the SLC1A3 level
was generally unaltered. Data from Oncomine (www.oncomine.org; [26].
Additional file 2: Figure S2. Nucleus counting after treatment of
parental and drug-resistant HCT116 and LoVo cells with DL-TBOA.
Parental and drug-resistant HCT116 and LoVo cell lines seeded in 96-well
dishes were exposed to SN38 (0.1 or 0.8 μM) or oxaliplatin (0.8 or 20 μM),
alone or in combination with 70 or 350 μM DL-TBOA as indicated, for
48 h. Cells were washed in PBS, fixed in 2 % paraformaldehyde and nuclei
were stained with DAPI. The number of adherent cells was determined
by automated counting using an OPERA confocal microscope. (A-B)
Parental HCT116 cells. (C) SN38 resistant HCT116 cells. (D) Oxaliplatin-resistant
HCT116 cells. (E-F) Parental LoVo cells. (G) SN38 resistant LoVo cells. (H)
Oxaliplatin-resistant LoVo cells. Data are means with S.E.M. error bars of 3
independent experiments. Values are normalized to those of untreated cells.
Additional file 3: Figure S3. Effects of DL-TBOA on cell death and
survival parameters after chemotherapy treatment of HCT116 cells.
Parental and drug-resistant HCT116 cell lines seeded in 6-well dishes
were exposed to SN38 (0.8 μM) or oxaliplatin (20 μM), alone or in
combination with 350 μM DL-TBOA as indicated, for 24 h. Equal amounts
of protein per lane were separated by SDS-PAGE and the protein levels
of p21, and PARP-1 (full-length and cleaved, the latter indicated by
arrowheads) were determined by Western blotting. Top: Representative
Western blots, with p150 as loading control. Bottom: Densitometric
quantifications based on 3 independent experiments per condition.
Data are means with S.E.M. error bars of 3 independent experiments. *)
p < 0.05, **) p < 0.01, ***) p < 0.001,****) p < 0.0001 compared to the
control group without drug or TBOA treatment; #) p < 0.05 compared to
controls without TBOA treatment. Two-way ANOVA with Tukey post-test.
Additional file 4: Figure S4. Effects of DL-TBOA on cell death and
survival parameters after chemotherapy treatment of LoVo cells. Parental
and drug-resistant LoVo cell lines seeded in 6-well dishes were exposed
to SN38 (0.8 μM) or oxaliplatin (20 μM), alone or in combination with
350 μM DL-TBOA as indicated, for 24 h. Equal amounts of protein per
lane were separated by SDS-PAGE and the protein levels of p21, and
PARP-1 (full-length and cleaved, the latter indicated by arrowheads) were
determined by Western blotting. Top: Representative Western blots, with
p150 as loading control. Bottom: Densitometric quantifications based on
3 independent experiments per condition. Data are means with S.E.M.
error bars of 3 independent experiments. *) p < 0.05, **) p < 0.01, ***)p < 0.001,****) p < 0.0001 compared to the control group without drug or
TBOA treatment; Two-way ANOVA with Tukey post-test.
Additional file 5: Figure S5. Effects of DL-TBOA on proliferation after
chemotherapy treatment. Parental and drug-resistant HCT116 (A) and
LoVo (B) cell lines seeded in 6-well dishes were exposed to SN38 (0.8 μM)
or oxaliplatin (20 μM) alone or in combination with 350 μM DL-TBOA as
indicated, for 24 h. Equal amounts of protein per lane were separated by
SDS-PAGE and the protein levels of phosphorylation of retinoblastoma
protein on Ser 807/811 (pRb) were determined by Western blotting. Top:
Representative Western blots, with β-actin as loading control. Bottom:
Densitometric quantifications based on 3 independent experiments per
condition. Data are means with S.E.M. error bars of 3 independent
experiments. Two-way ANOVA with Tukey post- test.
Additional file 6: Figure S6. SLC1A1 overexpression has no detectable
effect on cell death- and survival parameters tested. Representative blot
data of 3 independent experiments of HCT116 (A) or LoVo (B) cell lines,
in absence or presence of transient overexpression of wild type SLC1A1
(pSLC1A1) or corresponding empty vector (pcDNA3.1), followed by 24 h
of chemotherapeutic treatment (0.8 μM SN38 or 20 μM Oxa). The protein
levels of SLC1A1, p53, p21, and PARP-1 (full-length and cleaved, the latter
indicated by arrowheads) were determined by Western blotting. p150 is
shown as a loading control.
Additional file 7: Figure S7. Subcellular localization of SLC1A1, nuclei,
and F-actin in parental and resistant CRC cells-effects of chemotherapy
and DL-TBOA. (A) Immunofluorescence images of parental (PAR), SN38
resistant and oxaliplatin resistant HCT116 cells treated or not for 48 h
with 350 μM DL-TBOA, and stained with antibody against SLC1A1 (green)
and with DAPI (blue) and Rhodamine-conjugated phalloidin (red) to
visualize localization of nuclei and F-actin, respectively. (B) Parental and
SN38-resistant HCT116 cells treated for 48 h with 0.8 μM SN38 in the
absence or presence of 350 μM DL-TBOA, and stained as in A. (C)
Parental and oxaliplatin-resistant HCT116 cells treated for 48 h with
20 μM oxaliplatin in the absence or presence of 350 μM DL-TBOA, and
stained as in A. All conditions are representative of 2 or 3 independent
biological replicates in duplicate. Scale bar: 10 μm.Abbreviations
CRC: Colorectal cancer; CTR1: Cu2+-transporter-1; EAAT: Excitatory amino
acid transporter; GSH: Reduced glutathione, PARP, poly-ADP ribose;
pRb: Phospho-Retinoblastomaprotein; SLC: Solute carrier; DL-TBOA:
DL-Threo-β-Benzyloxyaspartic acid.
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